EICHORCondition: RSV Infection · Sponsor: Gilead Sciences
The goal of this clinical study was to learn more about the study drug, obeldesivir (ODV; GS-5245), and how safe and effective it was in treating nonhospitalized adults with acute respiratory syncytial virus (RSV) infection. The researchers wanted to see if obeldesivir can help participants' symptoms get better faster. The primary objectives of this study were to evaluate the efficacy of ODV in reducing the duration of symptoms and to evaluate the safety and tolerability of ODV in nonhospitalized adult participants with acute RSV infection.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Central Alabama Research | Birmingham, Alabama, United States | — |
| Cullman Clinical Trials | Cullman, Alabama, United States | — |
| Lakeview Clinical Research, LLC | Guntersville, Alabama, United States | — |
| Headlands Research-Scottsdale | Scottsdale, Arizona, United States | — |
| Epic Medical Research-Surprise | Surprise, Arizona, United States | — |
| Clearview Medical Research, LLC | Canyon Country, California, United States | — |
| Kaiser Permanente Fontana Medica Center | Fontana, California, United States | — |
| University of California, San Francisco-Fresno | Fresno, California, United States | — |
| Downtown L.A. Research Center, Inc. | Los Angeles, California, United States | — |
| L.A. Universal Research Center, INC. | Los Angeles, California, United States | — |
| Stanford | Palo Alto, California, United States | — |
| National Institute of Clinical Research, Inc | Pomona, California, United States | — |
+ 109 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06585150